Effective as of June, 2021.

Terms of Use

These Terms of Use are a binding agreement between you and Zealand Pharma A/S and its affiliates (“Zealand”) and govern your access and use of the website (the “Website”), which includes any information, data, tools, products, services and other content (together, “Content”) available on or through the Website, and provided for general information and educational purposes only.

PLEASE READ THESE TERMS OF SERVICE CAREFULLY BEFORE ENTERING THE WEBSITE. EACH TIME YOU ENTER THE WEBSITE, YOUR USE INDICATES YOUR FULL ACCEPTANCE OF AND AGREEMENT TO ABIDE BY THESE TERMS OF SERVICE IN THEIR THEN CURRENT FORM. IF YOU DO NOT ACCEPT THE TERMS AND CONDITIONS STATED IN THESE TERMS OF SERVICE, PLEASE EXIT THE WEBSITE.

As we may revise these Terms of Service from time to time, you should review them periodically. Zealand grants you a limited right to use the Website only for your own private, non-commercial informational purposes, and to print pages from the Website only in connection with that use.

By using this Website, you represent that you are at least 18 years old.

This Website Does Not Provide Medical or Professional Services Advice

NO INFORMATION IN THIS WEBSITE IS PROVIDED WITH THE INTENTION TO GIVE MEDICAL ADVICE OR INSTRUCTIONS ON THE ACCURATE USE OF ZEALAND PRODUCTS. ZEALAND CANNOT ANSWER UNSOLICITED E-MAILS REQUESTING PERSONAL MEDICAL ADVICE.

VISITORS SHOULD ALWAYS CONSULT A HEALTHCARE PROFESSIONAL PRIOR TO MAKING ANY DECISIONS, OR UNDERTAKING ANY ACTIONS OR NOT UNDERTAKING ANY ACTIONS, RELATED TO ANY HEALTH CARE PROBLEM OR ISSUE YOU MIGHT HAVE AT ANY TIME, NOW OR IN THE FUTURE. You should not construe Zealand’s publication of this content as an endorsement by Zealand of the views expressed herein, or any warranty or guarantee of any strategy, recommendation, treatment, action or application of medication or preparation made by the author of the content.

Privacy

Zealand’s Privacy Policy is a part of these Terms of Use. Use of this Website indicates your consent to the collection and use of your Personal Information as set forth in the Privacy Policy.

Intellectual Property Rights

The Website and the Content contain copyrighted materials, trademarks, and other proprietary materials that are owned by Zealand, its affiliates and/or third parties and are protected by intellectual property laws of the United States and other countries. You should assume that all Content of the Website is copyrighted unless otherwise noted. No Content from this Website or any Website owned, operated, licensed, or controlled by Zealand may be copied, reproduced, republished, uploaded, posted, downloaded, published, transmitted, or distributed in any way. Modification of the materials or use of the materials, including creating derivative works, for any other purpose is a violation of Zealand’s copyright and other proprietary rights. You may not transfer or sell any Content, including any text, graphics, logos and other source-identifying symbols, designs, icons, images, or other information, software or code obtained from the Website. For purposes of these terms, the use of any such material on any other Website or networked computer environment is prohibited. In addition, you are prohibited from decomposing, decompiling, reverse engineering, disassembling or otherwise deconstructing all or any portion of the Website. Any product, process or technology described in this Website may be the subject of other intellectual property rights reserved by Zealand or its affiliates and are not licensed hereunder. You have no right, title or interest (and no copyright, trademark or other intellectual property right) in or to the Website or any materials and you agree not to “frame” or “mirror” the Website. Zealand reserves all of its intellectual property rights in the Website, and these Terms of Use do not grant you any right or license with respect to any such intellectual property except as provided by this paragraph.

Product names, logos, trademarks, and service marks that are used or displayed on the Website (collectively, the “Trademarks”) are registered or unregistered trademarks and the exclusive property of Zealand. No use of the Trademarks may be made without Zealand’s prior written authorization, except to identify the product or services of the company. Other product names, logos, trademarks, and service marks appearing on the Website that are not owned by Zealand may not be used without express permission from their respective owners.

Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right, either express or implied, under any intellectual property of Zealand, or any third party.

Links

For your convenience, this Website may be linked to other Websites on the World Wide Web that are not under the control of or maintained by Zealand. Such links do not constitute an endorsement by Zealand of any such Websites. Furthermore, Zealand does not control the content on such Websites, and Zealand does not make any express or implied warranties with regard to the information, material, products, or services that are contained on or accessible through such linked Websites. Zealand disclaims any and all liability and responsibility for such content and privacy practices found on third party Websites hyperlinked from the Website.

You are free to establish a hypertext link to this Website so long as the link does not state or imply any endorsement or sponsorship of you, your company, or your Website by Zealand. Without the prior written permission of Zealand, you may not frame or scrape any of the content on the Website nor incorporate into another Website or other service any intellectual property of Zealand. Links to this Website from other Websites should be text-only and may not include Zealand’s logo or other intellectual property. We strictly prohibit any suggestions of Zealand’s endorsement or recommendation of a specific company, product, or service.

User Responsibility; Limitations on Liability; Disclaimer of Warranties

Each person assumes full responsibility and all risks arising from use of the Website.

IN NO EVENT, INCLUDING BUT NOT LIMITED TO NEGLIGENCE, SHALL ANY OF ZEALAND, THEIR AFFILIATES, AND THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, REPRESENTATIVES, DATA PROVIDERS, AND LICENSORS AND THEIR RESPECTIVE HEIRS AND ASSIGNS BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DAMAGES OF ANY KIND OR NATURE, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, SPECIAL (INCLUDING LOSS OF PROFIT), PUNITIVE, OR OTHER DAMAGES ARISING FROM OR IN CONNECTION WITH THE EXISTENCE OR USE OF THE WEBSITE, REGARDLESS OF WHETHER ZEALAND, OR ANY OF THE OTHER ENTITIES OR PERSONS LISTED ABOVE HAS BEEN ADVISED AS TO THE POSSIBILITY OF SUCH DAMAGES. THIS INCLUDES DAMAGES TO, OR FOR VIRUSES THAT MAY INFECT YOUR COMPUTER EQUIPMENT.

IF YOU RELY ON THIS WEBSITE OR ANY INFORMATION, PRODUCT OR SERVICE AVAILABLE THROUGH THIS WEBSITE, YOU AGREE THAT YOU DO SO AT YOUR OWN RISK. THERE MAY BE DELAYS, OMISSIONS, INTERRUPTIONS, INACCURACIES, AND/OR OTHER PROBLEMS WITH THE INFORMATION, PRODUCTS, AND SERVICES PUBLISHED ON OR PROMOTED OVER THIS WEBSITE.

WITHOUT LIMITING THE FOREGOING, EVERYTHING ON THE WEBSITE IS PROVIDED TO YOU “AS IS” AND ZEALAND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE WITH RESPECT TO THE WEBSITE.

ZEALAND HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, CREATED BY LAW, CONTRACT OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, OR NON-INFRINGEMENT.

ZEALAND MAKES NO REPRESENTATION OR WARRANTIES THAT ACCESS TO THE WEBSITE WILL BE AVAILABLE ON A TIMELY BASIS, WILL BE UNINTERRUPTED, OR THAT THE DATA CONTAINED ON THE WEBSITE WILL BE TIMELY OR ERROR FREE.

Please note that some jurisdictions may not allow the exclusion of implied warranties, so some of the above exclusions may not apply to you. Check your local laws for any restrictions or limitations regarding the exclusion of implied warranties. To the extent that Zealand may not, as a matter of applicable law, disclaim any implied warranty or limit its liabilities, the scope and duration of such warranty and the extent of Zealand’s liability will be equal to the minimum permitted under such applicable law.

Indemnification

YOU AGREE TO INDEMNIFY AND HOLD HARMLESS ZEALAND, ITS AFFILIATES, AGENTS, VENDORS AND LICENSORS, AND THEIR RESPECTIVE EMPLOYEES, OWNERS AND REPRESENTATIVES AGAINST ANY AND ALL CLAIMS, OF WHATEVER NATURE, THAT ARISE OUT OF ANY BREACH BY YOU OF THIS AGREEMENT OR YOUR USE OF THIS WEBSITE, TO THE FULLEST EXTENT ALLOWED BY LAW.

You further agree that any claim related to this Website must be filed within one year after it arises.

Non-Personal Data

Any non-Personal Data that you transmit to, or post on, this Website by electronic mail or otherwise, including any data, questions, comments, suggestions, or the like, is, and will be treated as, non-confidential and nonproprietary data, and Zealand shall have no obligation of any kind with respect to such data. Zealand and any of its affiliates may use such data for any purpose whatsoever in accordance with applicable laws and regulations, including, but not limited to, the following purposes: reproduction, disclosure, transmission, publication, broadcast, and further posting. Further, we and any of our affiliates shall be free to use such data, including, but not limited to, any ideas, concepts, know-how, or techniques contained therein, for any purpose whatsoever, including, but not limited to, researching, developing, manufacturing, and marketing products incorporating such data. Please consult our Privacy Policy for more information.

Social Media

Twitter, LinkedIn and other social media pages for Zealand are designed to facilitate conversations about our business, core values, career opportunities and advances in healthcare. These pages are not to be used as a forum for discussing specific products (whether Zealand products or another company’s products).

We may not always be able to retweet or otherwise publicly respond to your tweets, or publicly respond to your comments on our LinkedIn or other social media pages. We also do not continuously monitor these accounts, so please be patient with us. We do want to connect with you – if you have questions or you need to reach us directly, see the Contact Us section of this Website.

Zealand is not responsible for any tweets or comments from third-parties, and tweets or comments tagging Zealand or mentioning Zealand, its products or product candidates or its business or operations do not necessarily reflect our views. Zealand did not create and does not control the user-generated content posted by third-party organizations or individuals, including those in response to tweets or status updates on Zealand’s LinkedIn or other social media pages. Zealand reserves the right, but is not obligated, to remove content from our social media pages or block users who post content for reasons such as, but not limited to: making statements about unapproved uses of Zealand products or making statements that are or contain information that is unlawful, non-compliant, confidential, offensive, misleading, factually inaccurate, infringes a copyright or other intellectual property rights, or that we deem to be otherwise inappropriate.

Location and Governing Law

This Website is operated by Zealand US, Inc., a US subsidiary of Zealand Pharma A/S. The laws of the Commonwealth of Massachusetts shall govern these terms and conditions, without reference to its choice of law rules. Zealand makes no representation that the information in the Website is appropriate or available for use in other locations, and access to the Zealand Website from territories where the content of the Zealand Website may be illegal is prohibited. Those who choose to access the Zealand Website from other locations do so on their own initiative and are responsible for compliance with applicable local laws. Nothing contained on the Website should be construed as solicitation or promotion for any product or for the use of any product in a way which is not authorized by the country in which the reader is physically located. This Website provides information about products or uses that may not be available in particular countries. Some of the products mentioned may in certain countries be approved or cleared by regulatory authorities for sale or use with different indications, dosages, and restrictions.

Forward-Looking Statements

This Website contains information that is forward-looking and involves risks and uncertainties, including, without limitation, risks and uncertainties of research and development, clinical development, regulatory approvals and the regulatory process, our reliance on third-party manufacturers, product commercialization, competition, patents, product liability, and third party reimbursement, and other risks and uncertainties detailed from time to time in our periodic reports filed with the Securities and Exchange Commission. Actual results may differ materially from such forward-looking information.

Reservation of Rights

Zealand reserves the right to alter or delete material from this Website at any time without notice. Please check often for updates, as we reserve the right, in our sole discretion, to modify these Terms of Use at any time, and your use of the Website indicates your acceptance of any revisions to these terms.

These Terms of Use and any other terms and conditions of service on the Website constitute the entire agreement between you and Zealand and govern your use of the Website. Zealand’s failure to enforce any right or provision of these Terms of Use shall not constitute a waiver of such right or provision. If any provision of these Terms of Use is unlawful, void, or unenforceable, then it shall be severed and shall not affect the validity and enforceability of any Terms of Use. If any provision of these Terms of Use is held to be invalid or unenforceable in any jurisdiction, such provision shall be deemed modified to the minimum extent necessary so that such provision shall no longer be held to be invalid or unenforceable, and these Terms of Use shall be interpreted so as to achieve the intent expressed herein to the greatest extent possible in the jurisdiction in question. Any such modification, invalidity or unenforceability shall be strictly limited both to such provision and to such jurisdiction.

Zealand may assign its ownership, control, or other rights to any party at any time without any notice to you. Your rights and duties cannot be assigned without Zealand’s written consent. Nothing in these Terms of Use provides any third party with any remedy, claim, or cause of action.

Questions

If you have any questions about these Terms of Use, please contact the relevant individual listed in the Contact Us section of this Website.

INDICATION
INDICATION AND IMPORTANT SAFETY INFORMATION

ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

IMPORTANT SAFETY INFORMATION
Contraindications

ZEGALOGUE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure and in patients with insulinoma because of the risk of hypoglycemia.

plus icon
minus icon
INDICATION

ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications

ZEGALOGUE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure and in patients with insulinoma because of the risk of hypoglycemia.

Warnings and Precautions

ZEGALOGUE is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon products may produce an initial increase in blood glucose; however, ZEGALOGUE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. ZEGALOGUE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of ZEGALOGUE, give glucose orally or intravenously.

Allergic reactions have been reported with glucagon products; these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

ZEGALOGUE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for ZEGALOGUE administration to be effective. Patients with these conditions should be treated with glucose.

Adverse Reactions 

The most common adverse reactions (≥2%) associated with ZEGALOGUE in adults were nausea, vomiting, headache, diarrhea and injection site pain; in pediatrics: nausea, vomiting, headache and injection site pain.

Drug Interactions

Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given ZEGALOGUE. In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may produce hypoglycemia. ZEGALOGUE may increase the anticoagulant effect of warfarin.

Please see Full Prescribing Information.

References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. Hövelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care. 2018;41(3):531-537. doi:10.2337/dc17-1402

References: 1. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care. 2015;38(8):1583-1591. doi:10.2337/dc15-0279 2. Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS One. 2015;10(6):e0126427. doi:10.1371/journal.pone.0126427 3. American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(suppl 1):S73-S84. doi:10.2337/dc21-S006 4. American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(suppl 1):S66-S76. doi:10.2337/dc20-S006

References: 1. American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(suppl 1):S73-S84. doi:10.2337/dc21-S006 2. Cobb E, Watson N, Wardian J, Morrow C, Sauerwein T. Glucagon kits: are your patients prepared for a hypoglycemic emergency? AADE in Practice. 2017;5(1):12-17. doi:10.1177/2325160316677575 3. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care. 2015;38(8):1583-1591. doi:10.2337/dc15-0279 4. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021.

References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. Pieber TR, Aronson R, Hövelmann U, et al. Dasiglucagon: a next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia: results of phase 3 randomized double-blind clinical trial. Diabetes Care. Preprint posted online April 21, 2021. doi:10.2337/DC20-2995 3. Data on file. Zealand Pharma A/S; 2021.

References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. Battelino T, Tehranchi R, Bailey T, et al. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: results of a phase 3, randomized controlled trial. Pediatr Diabetes. Preprint posted online May 2, 2021. doi:10.1111/pedi.13220

Reference: Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021.

References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. ZEGALOGUE NDA 214231 approval letter, March 22, 2021. Accessed March 26, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/214231Orig1s000ltr.pdf

References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. Hövelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care. 2018;41(3):531-537. doi:10.2337/dc17-1402 3. Macchi F, Wenander C, Lundholt BK. Dasiglucagon is a novel stable glucagon analog with fast glucose response following subcutaneous injection in hypoglycemic rats. Poster presented at: Virtual European Association for the Study of Diabetes Annual Meeting 2020; September 21-25, 2020.

Reference: Zealand Pharma A/S. About us. Accessed March 23, 2021. https://www.zealandpharma.com/about-us

close button
ZEGALOGUE® vertical logo

Are you a healthcare professional?

The information in this section of the website is intended for US healthcare professionals only.

ZEGALOGUE® vertical logo

Are you ready to leave?

You are now leaving ZEGALOGUE.com/hcp.

By clicking the “Continue” button below, you will be taken to a website that may contain links or references to other websites in which our privacy policy may not apply. We encourage you to read the privacy policy of every website you visit. By clicking the “No thanks” button below, you will be taken to the page you were on previously.

TERMS AND CONDITIONS
Patient Instructions: The ZEGALOGUE® (dasiglucagon) injection Co-Pay Savings Card Program is ONLY valid for patients with commercial (private) insurance. In order to redeem this offer, you must have a valid prescription for ZEGALOGUE and you may not be enrolled in a state or federally funded prescription benefit program, including, but not limited to, Medicare (Parts A, B, C, or D), Medicaid (including Managed Medicaid), Veterans Affairs (VA), Department of Defense (DOD), or TRICARE. You are responsible for the first $25 and the card pays the remainder per prescription, up to a maximum of 12 fills per calendar year. Follow instructions provided by your doctor. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section below, including that you will not seek reimbursement for any part of the benefit received through this offer from any third-party payer, including any health savings, flexible spending, or other healthcare reimbursement account. Patients with questions about the offer should call 1-877-501-ZEGA (9342). THIS OFFER IS NOT INSURANCE.

Pharmacist: As a condition of payment, when you apply this offer, you are certifying that you have not submitted a claim for reimbursement under any federal, state, or other governmental programs including, without limitation, Medicare, Medicaid, VA, DOD, TRICARE, for this prescription and will not seek reimbursement from health insurance or any third party for any part of the benefit the patient receives through this program. Participation in this program must comply with all applicable laws and regulations as a pharmacy provider. By participating in this program, you are certifying that you will comply with the terms and conditions described in the Restrictions section below.

Pharmacist Instructions for a Patient With an Eligible Third-Party Payer: Submit the claim to the primary Third-Party Payer first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB (coordination of benefits) with patient responsibility amount and a valid Other Coverage Code, (e.g., 8). The patient is responsible for the first $25 and the card pays the remainder per prescription, up to 12 fills per calendar year. Reimbursement will be received from CHANGE HEALTHCARE.

A valid Other Coverage Code is required. For any questions regarding CHANGE HEALTHCARE online processing, please call the Help Desk at 1-800-422-5604.

Restrictions: This offer is valid in the United States. This offer is not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, VA, DOD, or TRICARE, or other federal or state health programs (such as medical assistance programs). If the patient is eligible for drug benefits under any such program or is Medicare-eligible and enrolled in employer-sponsored group waiver health plans or government-subsidized prescription drug benefit programs for retirees, the patient cannot use this offer. By using this offer, the patient and pharmacist certify that they will comply with any terms or requirements imposed on patients or providers by the health insurance to notify the health insurance plan of the existence and/or value of this offer. This offer is not valid for patients under 6 years of age. It is illegal to (or offer to) sell, purchase, or trade this offer. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Void where prohibited by law. This is not insurance. Program managed by ConnectiveRx on behalf of Zealand Pharma. The parties reserve the right to rescind, revoke, or amend this offer without notice at any time.

ZEGALOGUE® vertical logo

Please select the quantity of co-pay savings cards you would like to download for your eligible patients. 

Each card has a unique ID number.
Please do not make copies.
Downloading may take a few seconds.